{"transactions":[{"id":4622536,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":57500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":26.88,"expiration_date":"2031-01-21","underlying":"Common Stock","underlying_shares":57500},"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622535,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":15.46,"expiration_date":"2030-01-31","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622534,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17.96,"expiration_date":"2029-05-09","underlying":"Common Stock","underlying_shares":350},"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622533,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":39650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option is fully vested and exercisable."}],"balance_after":350,"derivative":{"exercise_price":17.96,"expiration_date":"2029-05-09","underlying":"Common Stock","underlying_shares":39650},"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622532,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":25.25,"expiration_date":"2028-05-10","underlying":"Common Stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622531,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":47746,"price":63.6126,"value":3037247.1996,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The weighted average sale price for the transaction reported was $63.6126, and the range of prices were between $63.47 and $63.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":98197,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622530,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":65104,"price":63.1205,"value":4109397.032,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The weighted average sale price for the transaction reported was $63.1205, and the range of prices were between $62.47 and $63.4650. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":145943,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622529,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":57500,"price":26.88,"value":1545600.0,"ownership":{"direct":true},"balance_after":211047,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622528,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":55000,"price":15.46,"value":850300.0,"ownership":{"direct":true},"balance_after":153547,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622527,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":350,"price":17.96,"value":6286.0,"ownership":{"direct":true},"balance_after":98547,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622526,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":270,"price":65.31,"value":17633.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":98197,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622525,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":63.6508,"value":190952.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $63.6508, and the range of prices were between $63.49 and $63.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided"}],"balance_after":98467,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622524,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":29021,"price":62.6552,"value":1818316.5592,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $62.6552 and the range of prices were between $62.41 and $63.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":101467,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622523,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":63907,"price":61.994,"value":3961850.558,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $61.994, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":130488,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622522,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":39650,"price":17.96,"value":712114.0,"ownership":{"direct":true},"balance_after":194395,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622521,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49363,"kind":"person","name":"ROTE WILLIAM E.","position":1,"cik":"0001698262","reported_name":"ROTE WILLIAM E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:57.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":39000,"price":25.25,"value":984750.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 271 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026."}],"balance_after":154745,"source":{"system":"sec-edgar","filing":"0001698262-26-000005","document":"form4-09182026_010952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1698262/000169826226000005/form4-09182026_010952.xml","form_type":"4"}},{"id":4622512,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-17","kind":"exercise","planned":true,"acquired":false,"shares":8282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":44837,"derivative":{"exercise_price":22.4,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":8282},"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622511,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":17717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The stock option is fully vested and exercisable."}],"balance_after":500,"derivative":{"exercise_price":26.88,"expiration_date":"2031-01-21","underlying":"Common Stock","underlying_shares":17717},"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622510,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":15.46,"expiration_date":"2030-01-31","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622509,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":11.25,"expiration_date":"2029-10-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622508,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":36526,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":28474,"derivative":{"exercise_price":8.93,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":36526},"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622507,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":1381,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":53119,"derivative":{"exercise_price":22.4,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":1381},"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622506,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":39283,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The stock option is fully vested and exercisable."}],"balance_after":18217,"derivative":{"exercise_price":26.88,"expiration_date":"2031-01-21","underlying":"Common Stock","underlying_shares":39283},"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622505,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":8282,"price":65.0709,"value":538917.1938,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The weighted average sale price for the transaction reported was $65.0709, and the range of prices were between $65.00 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":117066,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622504,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-17","kind":"exercise","planned":true,"acquired":true,"shares":8282,"price":22.4,"value":185516.8,"ownership":{"direct":true},"balance_after":125348,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622503,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":79113,"price":63.6546,"value":5035906.3698,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The weighted average sale price for the transaction reported was $63.6546, and the range of prices were between $63.50 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":117066,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622502,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":93604,"price":63.2471,"value":5920181.5484,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The weighted average sale price for the transaction reported was $63.2471, and the range of prices were between $62.50 and $63.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":196179,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622501,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":17717,"price":26.88,"value":476232.96,"ownership":{"direct":true},"balance_after":289783,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622500,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":55000,"price":15.46,"value":850300.0,"ownership":{"direct":true},"balance_after":272066,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622499,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":100000,"price":11.25,"value":1125000.0,"ownership":{"direct":true},"balance_after":217066,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622498,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":1431,"price":65.3093,"value":93457.6083,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The weighted average sale price for the transaction reported was $65.3093, and the range of prices were between $65.30 and $65.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":117066,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622497,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":1400,"price":63.6521,"value":89112.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $63.6521, and the range of prices were between $63.56 and $63.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":118497,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622496,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":27421,"price":62.5936,"value":1716379.1056,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $62.5936, and the range of prices were between $62.43 and $63.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":119897,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622495,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":71938,"price":62.0517,"value":4463875.1946,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $62.0517, and the range of prices were between $61.43 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at\neach price will be provided."}],"balance_after":147318,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622494,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":36526,"price":8.93,"value":326177.18,"ownership":{"direct":true},"balance_after":219256,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622493,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":1381,"price":22.4,"value":30934.4,"ownership":{"direct":true},"balance_after":182730,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622492,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49361,"kind":"person","name":"Heerma Peter","position":1,"cik":"0001789617","reported_name":"Heerma Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:35:06.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":39283,"price":26.88,"value":1055927.04,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,382 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026."}],"balance_after":181349,"source":{"system":"sec-edgar","filing":"0001789617-26-000004","document":"form4-09182026_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789617/000178961726000004/form4-09182026_010901.xml","form_type":"4"}},{"id":4622491,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":36392,"kind":"person","name":"Inrig Jula","position":1,"cik":"0001902368","reported_name":"Inrig Jula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D & CMO"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:33:51.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":32395,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":43605,"derivative":{"exercise_price":8.93,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":32395},"source":{"system":"sec-edgar","filing":"0001902368-26-000008","document":"form4-09182026_010947.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1902368/000190236826000008/form4-09182026_010947.xml","form_type":"4"}},{"id":4622490,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":36392,"kind":"person","name":"Inrig Jula","position":1,"cik":"0001902368","reported_name":"Inrig Jula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-18T01:33:51.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":400,"price":65.31,"value":26124.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":100491,"source":{"system":"sec-edgar","filing":"0001902368-26-000008","document":"form4-09182026_010947.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1902368/000190236826000008/form4-09182026_010947.xml","form_type":"4"}},{"id":4622489,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":36392,"kind":"person","name":"Inrig Jula","position":1,"cik":"0001902368","reported_name":"Inrig Jula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-18T01:33:51.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":1600,"price":63.685,"value":101896.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $63.685, and the range of prices were between $63.58 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":100891,"source":{"system":"sec-edgar","filing":"0001902368-26-000008","document":"form4-09182026_010947.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1902368/000190236826000008/form4-09182026_010947.xml","form_type":"4"}},{"id":4622488,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":36392,"kind":"person","name":"Inrig Jula","position":1,"cik":"0001902368","reported_name":"Inrig Jula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-18T01:33:51.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":17284,"price":62.6242,"value":1082396.6728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $62.6242, and the range of prices were between $62.40 and $63.365. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":102491,"source":{"system":"sec-edgar","filing":"0001902368-26-000008","document":"form4-09182026_010947.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1902368/000190236826000008/form4-09182026_010947.xml","form_type":"4"}},{"id":4622487,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":36392,"kind":"person","name":"Inrig Jula","position":1,"cik":"0001902368","reported_name":"Inrig Jula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-18T01:33:51.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":25390,"price":62.0167,"value":1574604.013,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $62.0167, and the range of prices were between $61.40 and $62.39. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":119775,"source":{"system":"sec-edgar","filing":"0001902368-26-000008","document":"form4-09182026_010947.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1902368/000190236826000008/form4-09182026_010947.xml","form_type":"4"}},{"id":4622486,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":36392,"kind":"person","name":"Inrig Jula","position":1,"cik":"0001902368","reported_name":"Inrig Jula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-18T01:33:51.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":32395,"price":8.93,"value":289287.35,"ownership":{"direct":true},"balance_after":145165,"source":{"system":"sec-edgar","filing":"0001902368-26-000008","document":"form4-09182026_010947.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1902368/000190236826000008/form4-09182026_010947.xml","form_type":"4"}},{"id":4622485,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49362,"kind":"person","name":"REED ELIZABETH E","position":1,"cik":"0001283303","reported_name":"REED ELIZABETH E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:32:52.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":15.46,"expiration_date":"2030-01-31","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001283303-26-000010","document":"form4-09182026_010948.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000128330326000010/form4-09182026_010948.xml","form_type":"4"}},{"id":4622484,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49362,"kind":"person","name":"REED ELIZABETH E","position":1,"cik":"0001283303","reported_name":"REED ELIZABETH E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2026-09-18T01:32:52.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":300,"price":65.31,"value":19593.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":105389,"source":{"system":"sec-edgar","filing":"0001283303-26-000010","document":"form4-09182026_010948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000128330326000010/form4-09182026_010948.xml","form_type":"4"}},{"id":4622483,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49362,"kind":"person","name":"REED ELIZABETH E","position":1,"cik":"0001283303","reported_name":"REED ELIZABETH E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2026-09-18T01:32:52.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":1400,"price":63.6902,"value":89166.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $63.6902, and the range of prices were between $63.59 and $63.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":105689,"source":{"system":"sec-edgar","filing":"0001283303-26-000010","document":"form4-09182026_010948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000128330326000010/form4-09182026_010948.xml","form_type":"4"}},{"id":4622482,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49362,"kind":"person","name":"REED ELIZABETH E","position":1,"cik":"0001283303","reported_name":"REED ELIZABETH E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2026-09-18T01:32:52.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":13874,"price":62.6326,"value":868964.6924000001,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $62.6326, and the range of prices were between $62.44 and $63.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":107089,"source":{"system":"sec-edgar","filing":"0001283303-26-000010","document":"form4-09182026_010948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000128330326000010/form4-09182026_010948.xml","form_type":"4"}},{"id":4622481,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49362,"kind":"person","name":"REED ELIZABETH E","position":1,"cik":"0001283303","reported_name":"REED ELIZABETH E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2026-09-18T01:32:52.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":21926,"price":62.0255,"value":1359971.113,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $62.0255, and the range of prices were between $61.44 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":120963,"source":{"system":"sec-edgar","filing":"0001283303-26-000010","document":"form4-09182026_010948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000128330326000010/form4-09182026_010948.xml","form_type":"4"}},{"id":4622480,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49362,"kind":"person","name":"REED ELIZABETH E","position":1,"cik":"0001283303","reported_name":"REED ELIZABETH E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and GC"}}],"security":"Common Stock","published_at":"2026-09-18T01:32:52.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":37500,"price":15.46,"value":579750.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 178 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026."}],"balance_after":142889,"source":{"system":"sec-edgar","filing":"0001283303-26-000010","document":"form4-09182026_010948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000128330326000010/form4-09182026_010948.xml","form_type":"4"}},{"id":4622479,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-17","kind":"exercise","planned":true,"acquired":false,"shares":108493,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":23.34,"expiration_date":"2029-01-04","underlying":"Common Stock","underlying_shares":108493},"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622478,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":195841,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option is fully vested and exercisable."}],"balance_after":108493,"derivative":{"exercise_price":23.34,"expiration_date":"2029-01-04","underlying":"Common Stock","underlying_shares":195841},"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622477,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":95666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option is fully vested and exercisable."}],"balance_after":304334,"derivative":{"exercise_price":23.34,"expiration_date":"2029-01-04","underlying":"Common Stock","underlying_shares":95666},"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622476,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":6802,"price":64.9508,"value":441795.3416,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":432886,"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622475,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":101691,"price":64.5866,"value":6567875.9406,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":439688,"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622474,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-17","kind":"exercise","planned":true,"acquired":true,"shares":108493,"price":23.34,"value":2532226.62,"ownership":{"direct":true},"balance_after":541379,"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622473,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":96125,"price":63.6389,"value":6117289.2625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":432886,"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622472,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":99716,"price":63.2593,"value":6307964.3588,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":529011,"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622471,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":195841,"price":23.34,"value":4570928.94,"ownership":{"direct":true},"balance_after":628727,"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622470,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":270,"price":65.31,"value":17633.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":432886,"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622469,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":3102,"price":63.6434,"value":197421.8268,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":433156,"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622468,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":28796,"price":62.6553,"value":1804222.0188,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":436258,"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622467,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":63498,"price":61.9945,"value":3936526.761,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":465054,"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622466,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":49360,"kind":"person","name":"Dube Eric M","position":1,"cik":"0001763494","reported_name":"Dube Eric M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:31:33.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":95666,"price":23.34,"value":2232844.44,"ownership":{"direct":true},"balance_after":528552,"source":{"system":"sec-edgar","filing":"0001763494-26-000007","document":"form4-09182026_010928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763494/000176349426000007/form4-09182026_010928.xml","form_type":"4"}},{"id":4622465,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:30:33.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17.44,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001943192-26-000006","document":"form4-09182026_010929.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000006/form4-09182026_010929.xml","form_type":"4"}},{"id":4622464,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:30:33.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":400,"price":65.31,"value":26124.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."}],"balance_after":87508,"source":{"system":"sec-edgar","filing":"0001943192-26-000006","document":"form4-09182026_010929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000006/form4-09182026_010929.xml","form_type":"4"}},{"id":4622463,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:30:33.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":1900,"price":63.6865,"value":121004.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $63.6865, and the range of prices were between $63.59 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":87908,"source":{"system":"sec-edgar","filing":"0001943192-26-000006","document":"form4-09182026_010929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000006/form4-09182026_010929.xml","form_type":"4"}},{"id":4622462,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:30:33.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":20735,"price":62.6079,"value":1298174.8065,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $62.6079, and the range of prices were between $62.38 and $63.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":89808,"source":{"system":"sec-edgar","filing":"0001943192-26-000006","document":"form4-09182026_010929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000006/form4-09182026_010929.xml","form_type":"4"}},{"id":4622461,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:30:33.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":27473,"price":61.9969,"value":1703240.8337,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $61.9969, and the range of prices were between $61.38 and $62.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":110543,"source":{"system":"sec-edgar","filing":"0001943192-26-000006","document":"form4-09182026_010929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000006/form4-09182026_010929.xml","form_type":"4"}},{"id":4622460,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:30:33.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":17.44,"value":348800.0,"ownership":{"direct":true},"balance_after":138016,"source":{"system":"sec-edgar","filing":"0001943192-26-000006","document":"form4-09182026_010929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000006/form4-09182026_010929.xml","form_type":"4"}},{"id":4622458,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":1625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":17875,"derivative":{"exercise_price":20.46,"expiration_date":"2035-01-31","underlying":"Common Stock","underlying_shares":1625},"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622457,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":3750,"derivative":{"exercise_price":22.4,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622456,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":27.5,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622455,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":300,"price":63.6633,"value":19098.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":42353,"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622454,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":800,"price":62.8481,"value":50278.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":42653,"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622453,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":4275,"price":62.135,"value":265627.125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":43453,"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622452,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":1625,"price":20.46,"value":33247.5,"ownership":{"direct":true},"balance_after":47728,"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622451,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":22.4,"value":28000.0,"ownership":{"direct":true},"balance_after":46103,"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622450,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":27.5,"value":68750.0,"ownership":{"direct":true},"balance_after":44853,"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4615777,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-09-11T20:05:18.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":26.52,"expiration_date":"2028-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001506916-26-000004","document":"form4-09112026_040911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000150691626000004/form4-09112026_040911.xml","form_type":"4"}},{"id":4615776,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-09-11T20:05:18.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17.44,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001506916-26-000004","document":"form4-09112026_040911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000150691626000004/form4-09112026_040911.xml","form_type":"4"}},{"id":4615775,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-11T20:05:18.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":3100,"price":68.088,"value":211072.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $68.088, and the range of prices were between $67.94 and $68.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":91500,"source":{"system":"sec-edgar","filing":"0001506916-26-000004","document":"form4-09112026_040911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000150691626000004/form4-09112026_040911.xml","form_type":"4"}},{"id":4615774,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-11T20:05:18.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":14000,"price":67.4634,"value":944487.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $67.4634, and the range of prices were between $66.93 and $67.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":94600,"source":{"system":"sec-edgar","filing":"0001506916-26-000004","document":"form4-09112026_040911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000150691626000004/form4-09112026_040911.xml","form_type":"4"}},{"id":4615773,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-11T20:05:18.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":1200,"price":66.15,"value":79380.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $66.15, and the range of prices were between $65.93 and $66.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":108600,"source":{"system":"sec-edgar","filing":"0001506916-26-000004","document":"form4-09112026_040911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000150691626000004/form4-09112026_040911.xml","form_type":"4"}},{"id":4615772,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-11T20:05:18.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":1700,"price":65.3917,"value":111165.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $65.3917, and the range of prices were between $64.835 and $65.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":109800,"source":{"system":"sec-edgar","filing":"0001506916-26-000004","document":"form4-09112026_040911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000150691626000004/form4-09112026_040911.xml","form_type":"4"}},{"id":4615771,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-11T20:05:18.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":26.52,"value":265200.0,"ownership":{"direct":true},"balance_after":111500,"source":{"system":"sec-edgar","filing":"0001506916-26-000004","document":"form4-09112026_040911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000150691626000004/form4-09112026_040911.xml","form_type":"4"}},{"id":4615770,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":45204,"kind":"person","name":"Meckler Jeffrey A","position":1,"cik":"0001506916","reported_name":"Meckler Jeffrey A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-11T20:05:18.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":17.44,"value":174400.0,"ownership":{"direct":true},"balance_after":101500,"source":{"system":"sec-edgar","filing":"0001506916-26-000004","document":"form4-09112026_040911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1506916/000150691626000004/form4-09112026_040911.xml","form_type":"4"}},{"id":1918,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-03T20:05:20.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":642,"price":66.37,"value":42609.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":118016,"source":{"system":"sec-edgar","filing":"0001943192-26-000005","document":"form4-09032026_040908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000005/form4-09032026_040908.xml","form_type":"4"}},{"id":681867,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17.44,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681866,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested and exercisable."}],"balance_after":5000,"derivative":{"exercise_price":17.44,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681865,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":900,"price":63.8557,"value":57470.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":61500,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681864,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":4100,"price":63.2659,"value":259390.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":62400,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681863,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":17.44,"value":87200.0,"ownership":{"direct":true},"balance_after":66500,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681862,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":500,"price":64.162,"value":32081.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":61500,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681861,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":2600,"price":63.4999,"value":165099.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":62000,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681860,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":1900,"price":62.5289,"value":118804.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":64600,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":681859,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:05:07.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":17.44,"value":87200.0,"ownership":{"direct":true},"balance_after":66500,"source":{"system":"sec-edgar","filing":"0001123343-26-000010","document":"form4-08192026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000112334326000010/form4-08192026_040801.xml","form_type":"4"}},{"id":730680,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":36392,"kind":"person","name":"Inrig Jula","position":1,"cik":"0001902368","reported_name":"Inrig Jula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-06-22T20:37:11.000Z","date":"2026-06-22","kind":"gift","planned":false,"acquired":false,"shares":468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a bona fide gift of 468 shares of common stock to a donor-advised fund.  The reporting person authorized the gift on June 16, 2026, and the transfer occurred on June 22, 2026."}],"balance_after":112770,"source":{"system":"sec-edgar","filing":"0001902368-26-000007","document":"form4-06222026_080607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1902368/000190236826000007/form4-06222026_080607.xml","form_type":"4"}},{"id":736062,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37659,"kind":"person","name":"Coughlin Timothy","position":1,"cik":"0001376043","reported_name":"Coughlin Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-16T20:46:48.000Z","date":"2026-06-12","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":26.52,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001376043-26-000010","document":"form4-06162026_080644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000137604326000010/form4-06162026_080644.xml","form_type":"4"}},{"id":736061,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37659,"kind":"person","name":"Coughlin Timothy","position":1,"cik":"0001376043","reported_name":"Coughlin Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T20:46:48.000Z","date":"2026-06-12","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":50.0747,"value":500747.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $50.0747, and the range of prices were between $50.00 and $50.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":56250,"source":{"system":"sec-edgar","filing":"0001376043-26-000010","document":"form4-06162026_080644.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000137604326000010/form4-06162026_080644.xml","form_type":"4"}},{"id":736060,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37659,"kind":"person","name":"Coughlin Timothy","position":1,"cik":"0001376043","reported_name":"Coughlin Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T20:46:48.000Z","date":"2026-06-12","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":26.52,"value":265200.0,"ownership":{"direct":true},"balance_after":66250,"source":{"system":"sec-edgar","filing":"0001376043-26-000010","document":"form4-06162026_080644.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000137604326000010/form4-06162026_080644.xml","form_type":"4"}}],"next_cursor":"2026-06-16T20:46:48.000000Z,736060"}